SK Biopharmaceuticals

The South Korean firm first gained US FDA approval for clinical testing for a new candidate drug substance in 1996. Currently, SK Biopharmaceuticals is conducting basic research for the development of innovative new drugs at the Bio Science Research Institute in Pangyo Techno-valley, Gyeonggi Province.

SK Biopharmaceuticals aims to grow into a Fully Integrated Global Pharmaceutical Company (Global FIPCO), equipped with an entire value chain ranging from development and manufacturing to commercialization via its own sales and marketing organization.

Latest SK Biopharmaceuticals News & Features